Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Using FDG-PET to Investigate the Dosing Schedule and Response of Combination SGN-15 (cBR96-Doxorubicin Immunoconjugate) and Docetaxel in Patients With Stage IV or Stage IIIB Non-Small Cell Lung Carcinoma Ineligible for Combined Modality Treatment With Curative Intent

NCT00086333 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT00086333
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00086333 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Using FDG-PET to Investigate the Dosing Schedule and Response of Combination SGN-15 (cBR96-Doxorubicin Immunoconjugate) and Docetaxel in Patients With Stage IV or Stage IIIB Non-Small Cell Lung Carcinoma Ineligible for Combined Modality Treatment With Curative Intent
Lead sponsor
Seagen Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2004
Completion date
December 31, 2005
Enrollment
30
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung carcinoma